A chat where you will be supported
Artes Electronics has launched an app for those who have been diagnosed with Skin Cancer.
Artes Electronics company has launched a new product - Artes Union app, where anyone who has been diagnosed with melanoma can communicate directly with people who have survived cancer or are currently under treatment.
90% of melanoma survivors (based on an independent survey) who have been treated and achieved remission admit that they lacked support from "equal" people, that is, patients with the same diagnosis. Especially in the first few days. At the moment of acceptance and awareness of the diagnosis, it is important not to lock yourself in, but to talk to someone who will understand and help calm down, and tune in to the treatment of skin cancer with new energy. People who have already encountered melanoma are willing to share their experience, so Artes Electronics caught fire with the idea to simplify such communication and create a special application.
After 11 months of development, Artes Electronics has launched a beta version of Artes Union chat. The application is free and is available for Android devices from today in Google play. The iOS version also appeared in the App Store at the end of June. Now operators from all over the world who have survived melanoma and other types of skin cancer are actively connected to the app.
A little bit about the product: the app got its name from the first Greek library known to man, Artes. This library included works on various spheres of life at that time, including medicine. This name perfectly describes the goal that is laid in the app - a comprehensive approach to a person. Therefore, the chat of warriors with melanoma is only the first step, in the future new features related to health and self-care will be added to the Artes Union app.
90% of melanoma survivors (based on an independent survey) who have been treated and achieved remission admit that they lacked support from "equal" people, that is, patients with the same diagnosis. Especially in the first few days. At the moment of acceptance and awareness of the diagnosis, it is important not to lock yourself in, but to talk to someone who will understand and help calm down, and tune in to the treatment of skin cancer with new energy. People who have already encountered melanoma are willing to share their experience, so Artes Electronics caught fire with the idea to simplify such communication and create a special application.
After 11 months of development, Artes Electronics has launched a beta version of Artes Union chat. The application is free and is available for Android devices from today in Google play. The iOS version also appeared in the App Store at the end of June. Now operators from all over the world who have survived melanoma and other types of skin cancer are actively connected to the app.
A little bit about the product: the app got its name from the first Greek library known to man, Artes. This library included works on various spheres of life at that time, including medicine. This name perfectly describes the goal that is laid in the app - a comprehensive approach to a person. Therefore, the chat of warriors with melanoma is only the first step, in the future new features related to health and self-care will be added to the Artes Union app.
List of literature
- Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069–80.
- Karjalainen S1, Salo H., Teppo L. Basal cell and squamous cell carcinoma of the skin in Finland. Site distribution and patientsurvival. Int J Dermatol. 1989 Sep; 28(7): 445–50.
- Bastiaens MT, Hoefnagel JJ, Bruijn JA et al. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 1998; 110:880–4.
- Luz FB, Ferron C., Cardoso GP. Surgical treatment of basal cell carcinoma: an algorithm based on the literature. An Bras Dermatol. 2015 May-Jun; 90(3): 377–83.
- Julien Lanoue, Gary Goldenberg. Basal Cell Carcinoma, А Comprehensive Review of Existing and Emerging Nonsurgical Therapies. J Clin Aesthet Dermatol. 2016 May; 9 (5): 26–36.]
- Vijlder, H., Sterenborg, H., Neumann, H., Robinson, D., Haas, E. (2012). Light Fractionation Significantly Improves the Response of Superficial Basal Cell Carcinoma to Aminolaevulinic Acid Photodynamic Therapy: Five-year Follow-up of a Randomized, Prospective Trial. Acta Dermato Venereologica, 92 (6), 641–647. doi: 10.2340/00015555-1448
- Lehmann, P. (2007). Methyl aminolaevulinate?photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. British Journal of Dermatology, 156(5), 793–801. doi: 10.1111/j.1365-2133.2007.07833.x.
- Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006 May; 45(5): 489–98.
- Wysong, A., Aasi, S. Z., Tang, J. Y. (2013). Update on Metastatic Basal Cell Carcinoma: A Summary of Published Cases From 1981 Through 2011. JAMA Dermatology, 149(5), 615.
- Sekulic A, Migden MR, Basset-Seguin N., Garbe C., Gesierich A., Lao CD., Miller C., Mortier L., Murrell DF., Hamid O., Quevedo JF., Hou J., McKenna E., Dimier N., Williams S., Schadendorf D., Hauschild A.; ERIVANCE BCC Investigators.Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: finalupdate of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 May 16; 17(1):3 32. doi: 10.1186/s12885-017-3286-5.
- Lear JT., Migden MR., Lewis KD., Chang ALS., Guminski A., Gutzmer R., Dirix L., Combemale P., Stratigos A., Plummer R., Castro H, Yi T., Mone M., Zhou J., Trefzer U., Kaatz M., Loquai C., Kudchadkar R., Sellami D., Dummer R. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.J Eur Acad Dermatol Venereol. 2018 Mar; 32 (3): 372–381. doi: 10.1111/jdv.14542. Epub 2017 Nov 6.
- Wieman TJ., Shively EH., Woodcock TM. Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer. N1983; 52 (9): 1583–1585.
- Coker DD, Elias EG, Viravathana T, et al. Chemotherapy for metastatic basal cell carcinoma. Arch Dermatol. 1983; 119 (1): 44–50.
- Guthrie TH., Jr, McElveen LJ., Porubsky ES., Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985; 55 (8): 1629–1632.
- Bason MM., Grant-Kels JM., Govil M. Metastatic basal cell carcinoma: response to chemotherapy. J Am Acad Dermatol. 1990; 22 (5 Pt 2): 905–908.
- Khandekar JD. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report of two patients. Arch Dermatol. 1990; 126 (12): 1,660.
- Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999; 22 (1): 32–34.
- Jefford M., Kiffer JD., Somers G., et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004; 74 (8): 704–705.
- Moeholt K., Aagaard H., Pfeiffer P., Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma-a review of the literature. Acta Oncol. 1996; 35 (6): 677–682.
- Carneiro BA., Watkin WG., Mehta UK., Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006; 24 (4): 396–400.